{"database": "lobbying", "table": "lobbying_activities", "rows": [[2465850, "b43efa7c-6cd5-43a1-b394-cc1ea7e5b51e", "Q2", "WINNING STRATEGIES WASHINGTON", 50796, "KALEO", 2020, "second_quarter", "PHA", "Pharmaceutical drug development, including epinephrine for anaphlylaxis; drug access and affordability issues", "Federal Aviation Administration (FAA),HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2020-07-15T10:48:06.507000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2465850"], "units": {}, "query_ms": 45.201434986665845, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}